ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2020. The put-call ratio across all filers is 1.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,243,515 | -74.7% | 782,085 | -0.8% | 0.00% | -77.8% |
| Q4 2022 | $4,911,520 | +37.7% | 788,366 | +520.0% | 0.02% | +63.6% |
| Q1 2021 | $3,566,000 | +51.9% | 127,146 | +40.8% | 0.01% | +57.1% |
| Q4 2020 | $2,347,000 | +243.1% | 90,272 | +390.7% | 0.01% | +250.0% |
| Q3 2020 | $684,000 | -64.1% | 18,395 | -50.5% | 0.00% | -50.0% |
| Q2 2020 | $1,906,000 | +71.4% | 37,162 | +5.4% | 0.00% | +33.3% |
| Q1 2020 | $1,112,000 | -88.7% | 35,256 | -78.6% | 0.00% | -85.0% |
| Q4 2019 | $9,810,000 | +2785.3% | 164,520 | +3400.4% | 0.02% | +1900.0% |
| Q1 2018 | $340,000 | -87.8% | 4,700 | -96.0% | 0.00% | -90.9% |
| Q3 2015 | $2,777,000 | -56.5% | 117,703 | +50.7% | 0.01% | -57.7% |
| Q2 2015 | $6,385,000 | -11.7% | 78,091 | 0.0% | 0.03% | -13.3% |
| Q1 2015 | $7,231,000 | +101.9% | 78,091 | -11.8% | 0.03% | +114.3% |
| Q4 2014 | $3,581,000 | – | 88,546 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |